Subglottic Stenosis
Conditions
Keywords
Subglottic Stenosis, Triamcinolone, Translaryngeal Endoscopic Mucosal Injection, Ultrasound-Guided Injection
Brief summary
This study employs a multicenter, randomized controlled trial method, where patients meeting the inclusion criteria for subglottic stenosis are randomly divided into two groups. These groups are respectively undergoing translaryngeal endoscopic mucosal injection and ultrasound-guided injection of triamcinolone treatment. The comparison will focus on various indicators such as therapeutic effect, incidence of adverse reactions, treatment costs, and hospital resource utilization between the two groups. The safety and effectiveness will be compared to determine the relative merits of the two treatment methods.
Interventions
PROCEDUREUltrasound-Guided
Ultrasound-Guided Triamcinolone Injection
PROCEDURETranslaryngeal Endoscopic Mucosal Injection
Translaryngeal Endoscopic Mucosal Injection of Triamcinolone
Sponsors
China-Japan Friendship Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* 1: Diagnosed with subglottic stenosis through laryngoscopic examination or imaging studies such as CT. * 2: Experiencing symptoms related to subglottic stenosis, such as breathing difficulties, hoarseness, etc.
Exclusion criteria
* 1: Severe cardiopulmonary dysfunction, patients extremely debilitated and unable to tolerate the procedure. * 2: Patients allergic to lidocaine, midazolam, triamcinolone, or any of their components. * 3: Pregnant or lactating women. * 4: Unstable angina, congestive heart failure, severe bronchial asthma. * 5: Severe hypertension and arrhythmias, hemodynamically unstable, and severe respiratory failure (PaO2 \<60mmHg after oxygen therapy or mechanical ventilation). * 6: Known coagulation dysfunction, inability to stop anticoagulants, antiplatelet agents, aspirin, or nonsteroidal anti-inflammatory drugs before treatment. * 7: Patients do not agree to participate in this study. * 8: Participation in other studies within the last three months and not withdrawn or concluded, or having received triamcinolone treatment less than 1 month ago. * 9: Researchers believe there are any circumstances making the patient unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Short-Term Postoperative Complications | one week after intervention | Follow-up on short-term postoperative complications (including pneumothorax, bleeding, wound infection, pain, fever, etc.) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall medical expenses incurred by patients | one week after intervention | Overall medical expenses incurred |
Countries
China
Contacts
Primary ContactGang Hou, PI
Backup ContactMingming Deng, Phd
Outcome results
None listed